אולתוטון 10 מג
abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 10 mg - octreotide
אולתוטון 20 מג
abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 20 mg - octreotide
אולתוטון 30 מג
abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 30 mg - octreotide
סיגניפור לאר 10 מג
medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 10 mg/vial - pasireotide
סיגניפור לאר 30 מג
medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 30 mg/vial - pasireotide
ביידוריון 2 מג
astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
סנדוסטטין 30 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סנדוסטטין 20 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סנדוסטטין 10 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סופרפאקט דפו 3 חודשים
sanofi - aventis israel ltd - buserelin acetate - קנים להשתלה - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).